Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
Metastatic bone and soft tissue sarcomas often relapse after chemotherapy (CHT) and molecular targeted therapy (mTT), maintaining a severe prognosis. A subset of sarcoma cancer stem cells (sCSC) is hypothesized to resist conventional drugs and sustain disease relapses. We investigated the immunother...
Main Authors: | Giulia Mesiano, Giovanni Grignani, Erika Fiorino, Valeria Leuci, Ramona Rotolo, Lorenzo D’Ambrosio, Chiara Salfi, Loretta Gammaitoni, Lidia Giraudo, Alberto Pisacane, Sara Butera, Ymera Pignochino, Marco Basiricó, Federica Capozzi, Anna Sapino, Massimo Aglietta, Dario Sangiolo |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-11-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1465161 |
Similar Items
-
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
by: V. Leuci, et al.
Published: (2018-05-01) -
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
by: Ramona Rotolo, et al.
Published: (2019-06-01) -
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
by: Philipp Wendel, et al.
Published: (2021-03-01) -
Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells
by: Rombo, Roman, et al.
Published: (2016-04-01) -
SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: a potential challenge for combination therapy
by: Eva eRettinger, et al.
Published: (2014-07-01)